Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11–13 weeks in preeclampsia

Recent Insights into the Role of the Insulin-Like Growth Factor Axis in Preeclampsia

“…The only so far published study that reported no change in IGFBP-3 levels in early stages of gestation is opposite to recent data that demonstrate an increase in IGFBP-3 concentration at 11-13 weeks in term but not in preterm preeclampsia not associated to uterine artery PI which is a known measure of impaired placental perfusion [Sifakis et al, 2011b]. Most likely, this finding could be the result of impaired glucose tolerance and increased insulin resistance as there is in vitro and in vivo evidence for a relationship between circulating IGFBP-3 levels and hyperglycemia and a IGFBP-3 potent insulin-antagonizing capability exerted either via IGF-independent pathways or by decreasing IGF-bioavailability.…”

RASSF1A in maternal plasma as a molecular marker of preeclampsia

“…Low levels of maternal serum pregnancy‐associated plasma protein A (PAPP‐A) and placental protein 13 (PP‐13), combined with increased uterine artery resistance, documented in the first half of pregnancy, have been linked with increased risk for PE manifested in later gestation . Other serum markers such as A disintegrin and metalloproteases (ADAM 12), placental growth hormone (PGH), insulin growth factor (IGF‐I) and insulin growth factor binding protein 1 and 3 (IGFBP‐1 and 3) in the first trimester of pregnancy have been also evaluated . Furthermore, transcriptional analysis of maternal blood has revealed biologically diverse fetal genes that may serve as baseline to compare fetuses affected by PE …”

Prediction of the preeclampsia: a view of biochemical markers

“…Such changes are detected by secretion of when we investigate the levels of the IGFBP-3, it elevates only in late-onset preeclampsia. In both cases, there is no correlation to a disturbed trophoblast invasion [70,71].…”